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Objectives. Zollinger-Ellison Syndrome (ZES) results in hypersecretion of gastric acid (via gastrinoma) leading to peptic ulcers,
diarrhea, and abdominal pain. We describe the novel discovery of hypertrophic, heterotopic gastric mucosa in the proximal
duodenal bulb in patients with ZES, which we hypothesize results in an increased incidence of postbulbar ulcers in patients
with ZES (a mechanism previously unreported). We determined the incidence of the novel ﬁnding of duodenal gastric oxyntic
hypertrophic heterotopia (GOH) in patients with ZES. Methods. Seven patients with ZES were enrolled. The diagnosis of ZES was
established by hypergastrinemia, gastric acid hypersecretion, and a positive secretin test or based on biopsy specimens (evaluated
via tissue staining). Basal acid output (BAO) and baseline gastrin secretion were determined by established methods. Endoscopic
examinations with methylene blue staining and biopsy of the gastric and duodenal mucosa were conducted in all patients every
3–6 months for an average of 5 years. Results. The duodenal mucosa demonstrated hypertrophic GOH in 5 out of 7 patients
with ZES and an intact stomach and duodenum. Biopsies from the bowel mucosa demonstrated patchy replacement of surface
epithelium by gastric-type epithelium with hypertrophic oxyntic glands in the lamina propria in 5 patients. Two of the patients
had no evidence of GOH in the duodenal bulb. Patients with GOH had an average serum gastrin level of 1245pg/mL and BAO
of 2.92mEq/hr versus 724pg/mL and 0.8mEq/hr in patients without GOH. Conclusions. This study demonstrated the presence of
duodenal mucosa with GOH in 5 out of 7 patients with ZES and an intact stomach and duodenum. The presence of hypertrophic
and heterotopic gastric mucosa is proposed to result from increased gastrin levels and may contribute to the increased incidence
of postbulbar ulcers in these patients.
Copyright © 2009 Emil Kohan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Zollinger Ellison Syndrome (ZES) is a rare gastrointestinal
syndrome that results from a gastrin-producing tumor
generally localized to either the pancreas or duodenum
[1]. The pathophysiological state resulting from ZES is
attributabletoexcessivereleaseofgastrinandtheconsequent
eﬀects of hypergastrinemia [1]. A substantial secretion of
acid results in damage to the mucosal lining of the GI
tract. Acid-associated severe and recurrent gastrointestinal
ulcerations with a high incidence of bleeding and perfo-
ration make gastric acid hypersecretion a major cause of
morbidity and mortality in patients with ZES. Additionally,
patients with ZES can develop esophagitis, duodenojejunitis,
maldigestion, and diarrhea that are often debilitating and
adversely aﬀect their quality of life [2]. In addition to the
eﬀects on gastric acid secretion, gastrin stimulates gastric
mucosal proliferation [3–5]. The eﬀect of gastrin on gastric
mucosa proliferation has been well explained and accounts
for the hyperplasia and hypertrophy of the parietal cell,
which has been illustrated in patients with ZES [6].
Heterotopic gastric tissue has been described as a con-
genital lesion in the duodenal bulb in between 0.5–2%
of the general population [7–10]. Mann et al. provide an
excellent description of heterotopic gastric tissue (GOH) in
the duodenal bulb and elucidate the diﬀerences between2 Diagnostic and Therapeutic Endoscopy
heterotopic gastric tissue and gastric metaplasia (GM) [11].
ItisimportantthatGOHandGMarecorrectlydiﬀerentiated
because of their diﬀerent clinical manifestations. GOH is
histopathologically and clinically diﬀerent from the much
more common duodenal metaplasia. These two lesions have
historically been mistaken as one and the same [11–14].
However the importance of diﬀerentiating between them is
underscored in the background of ZES. It is important that
GOH and GM are correctly diﬀerentiated because of their
diﬀerent clinical manifestations. GOH is benign, described
as a macroscopic lesion on endoscopic examination with
massesupto2.5cmormultiplepolypsupto10mmeach.On
histology,theselesionsdemonstratewell-diﬀerentiated,well-
organized gastric glands with mature structures including
chief cells, parietal cells, and mucus cells. GOH cannot
be diagnosed in the presence of H. pylori.G Mi sa l w a y s
acquired, seen as a microscopic lesion on endoscopy, and
often demonstrates mucus neck cells with occasional parietal
cells [11, 15, 16].
In this report, we describe the endoscopic and
histopathological characteristics of the novel ﬁnding of
hypertrophic, heterotopic duodenal gastric mucosa in
patients with Zollinger Ellison syndrome. The discovery
of heterotopic gastric mucosa within the duodenal bulb
during endoscopic biopsy is a relatively recent discovery, due
in part to the use of more slender endoscopes permitting
retroﬂexion within the duodenal bulb. This permits a full
examination of the duodenal bulb. Given that the majority,
if not all, of the patients with ZES have gastric mucosal
hyperplasia, we hoped that investigation of this group of
patients for the presence of heterotopic gastric mucosa in
the duodenal bulb would reveal unique, clinically relevant
ﬁndings. Although GOH is a benign ﬁnding in the general
population, duodenal hypertrophic heterotopic gastric
mucosa may contribute to postbulbar ulcerations commonly
seen in patients with ZES. An appreciation for this can also
be used to consider the diagnosis of ZES prior to gastric acid
secretory studies.
2.MaterialsandMethods
2.1. Patients. Seven subjects were enrolled in the study to
be evaluated for GOH. They were diagnosed with Zollinger
Ellison Syndrome using the following established criteria:
elevated serum gastrin (>1000pg/mL) in the presence of
gastric acid secretion (>15mEq/hr or >5mEq/hr if the
patient had previous gastric surgery) as well as a positive
provocative testing with secretin stimulation (a rise in serum
gastrin ≥200pg/mL after injection) or with calcium infusion
(a rise in serum gastrin ≥395pg/mL), a positive histological
diagnosis of gastrinoma, or a combination of these [17].
All subjects were over 18 years of age, and female subjects
were not pregnant and either postmenopausal or using
medically acceptable contraception. All patients presented
with abdominal symptoms, including pain and diarrhea, at
the time of diagnosis. Each subject had a comprehensive
history taken and underwent a complete physical exami-
nation. The prescreening evaluation included a complete
blood cell count, chemistry, liver function tests, gastrin,
thyroid function tests, pregnancy test (for premenopausal
women only), and urinalysis. During the study, vital signs
and EKGs were also monitored, and laboratory evaluations
were obtained at speciﬁed times.
The patients were enrolled with a mean age of 49.6 years
(range of 38–61 years). Five of the 7 patients were males, and
twofemales(Table 1).Theaveragetimesincethediagnosisof
ZES was 11.3 years (range of 1–25 years). Multiple endocrine
neoplasia type I (MEN I) was diagnosed in 3 of the patients.
None of the seven patients had been cured of ZES at the time
of study enrollment and none had received chemotherapy
prior to study enrollment. All of the patients were treated
with pantoprazole with an average dose of approximately
90mg daily (range of 80–160).
2.2. Endoscopic Evaluation. Patients underwent endoscopic
evaluation with a Pentax 2700 or 2900 endoscope following
intravenous sedation with midazolam and meperidine. The
endoscope was advanced to the duodenal bulb, inspection
was performed, and photography taken. Alcian blue was
used to highlight the contours of the gastric mucosa in
the duodenal bulb. Biopsies and photographs were taken
with the scope in the retroﬂexed position. Biopsies were
mounted and oriented and placed in formalin ﬁxative.
Patients underwent endoscopies at 3–6 month intervals for
over a period of four to ﬁve years to monitor any changes
related to disease and the eﬀect of PPI treatment.
2.3. Study Design. Subjects were evaluated for GOH as
described in “endoscopic evaluation.” The acid output (AO)
was determined as described previously [18]. The value of
AO was expressed in mEq/hr and calculated by determining
the total acid in four 15-minute gastric collections utilizing
a nasogastric tube. The tube was passed into the dependent
portion of the stomach, and its position was veriﬁed by the
water recovery method [18]. After aspiration of the residual
gastric content for approximately 15 minutes, basal acid
secretion was collected in 15-minute intervals for one hour
usinglowintermittentsuction.Gastricaspirateswereassayed
fortotalacidcontentbytitrationwith0.1MNaOHtopH7.0
at the time of collection.
3. Results
These demographic and gastric secretory data are consistent
with the majority of patients who are diagnosed with ZES
and who are under treatment with proton pump inhibitors
([17]—mentioned before). Diarrhea was the most common
symptom, followed by abdominal pain and nausea, for
subjects involved in this study.
Of the seven patients, with no prior gastric surgery and
an intact stomach and duodenum, ﬁve were diagnosed with
hypertrophicgastricoxynticheterotopias(GOH).Methylene
blue staining provided a better view of the hypertrophic,
heterotopic mucosa as methylene blue was only absorbed
by mature intestinal epithelium, not by gastric epithe-
lium (Figure 1), allowing for the identiﬁcation of gastric
mucosa in the duodenum. Biopsies from the small bowelDiagnostic and Therapeutic Endoscopy 3
Table 1: Patient demographics.
Subject Age Sex Race Time since ZES
diagnosed (yrs)
MEN-1 status Gastrin level
(pg/mL)







1 51 M Caucasian 4 Negative 711 0.1 pancreas No No
2 49 M Caucasian 12 Positive 3090 0.4 duodenum No Yes
3 61 F Caucasian 12 Negative 2050 0.8 pancreas No Yes
4 39 M Caucasian 25 Positive 737 1.5 pancreas No No
5 50 M Caucasian 5 Negative 194 2.8 pancreas No Yes
6 59 F Caucasian 20 Positive 121 0.6 pancreas No Yes
7 38 M Caucasian 1 Negative 770 10 unknown Yes Yes
mucosa in the ﬁve patients with hypertrophic GOH revealed
hypertrophic, well-organized, and well-diﬀerentiated gastric
glands complete with chief and parietal cells (Figure 2).
These duodenal biopsies with hypertrophic GOH also had
portions demonstrating duodenal mucosa with multifocal
gastric metaplasia of variable degrees in four patients. There
was subtotal versus patchy replacement of the surface epithe-
lium with underlying hypertrophic and mature oxyntic
glands in the lamina propria seen in each of these specimens.
Two of these ﬁve patients showed an immunoproﬁle of
hyperplasia of gastrin producing endocrine cells. The deep
mucosa and submucosa were invested with prominent
Brunner’s glands. Other specimens taken from the duodenal
bulbshowedareasofduodenalmucosaandadjacentoxyntic-
type mucosa with overlying foveolar epithelium. Endocrine
hyperplasia or neoplasia was mostly absent from the duode-
nal bulb. In one patient, the gastric-type mucosa contained
occasional endocrine cells. On multiple biopsies, both in
areas of oxyntic heterotopia and in areas with Brunner’s
glands, mucosa was present with nuclei displaced oﬀ to
the side. The nuclei did not display either polymorphism
or pleomorphism (Figure 3). The usual scant inﬂammatory
cells are present within the lamina propria. In general,
neither the gastrinoma or carcinoid tumors were present.
In most cases, hypertrophic oxyntic gastric mucosa was
presentinthesectionswithnormalarchitecture.Theparietal
cells were hyperplastic, hypertrophic, and displayed apical
protrusions.
Biopsies of the two patients who did not have hyper-
trophic GOH were conducted. Representative histology of
their duodenal bulb mucosa is included (Figure 2). As was
expected from gross features on endoscopic exam, histology
lacking the ectopic gastric tissue that deﬁnes GOH is
seen. The representative ﬁgure demonstrates some villous
architecture alterations and gastric foveolar metaplasia, both
of which are consistent with peptic type injury commonly
seen in patients with ZES. The duodenal sections uninvolved
with GOH had relatively tall villi, short crypts, and many
mucinous glands both above and beneath the muscularis
mucosa. Helicobacter pylori was not present in any of the
cases.
Injury to the mucosa identiﬁed via endoscopic biopsy
in the enrolled patients demonstrated reduction in area
of mucosal alteration throughout the study while on PPI
therapy. In the cases of hypertorphic GOH, however, this
ectopic tissue remained present despite treatment and long-
termfollow-upviaserialendoscopythroughouttheduration
of the study period.
Patients with GOH had an average serum gastrin level
of 1245pg/mL (standard deviation of 1289) and BAO of
2.92mEq/hr (standard deviation of 4.1) versus 724pg/mL
(standard deviation of 1289) and 0.8mEq/hr (standard
deviation of 0.99) in patients without GOH. Due to limited
sample size in our study of patients with this rare condition,
statistical analysis utilizing student’s T-test comparing the
gastrin and acid output levels revealed no signiﬁcant diﬀer-
ences (P>. 05) in both cases; P = .42, P = .33, respectively.
4. Discussion
The major symptoms of Zollinger Ellison syndrome (related
toexcessivegastricacidsecretion)cannowbewellcontrolled
with the use of proton pump inhibitors. General recommen-
dations for the management of patients with ZES include
maintainingthelevelofacidsecretionatlessthen10mEq/hr.
Patients with MEN-I syndrome, GERD (gastroesophageal
reﬂux disease), or prior gastric acid reducing surgery should
be maintained at <5mEq/hr[19]. PPI medication was able
to control acid production, evidenced by reduction in gastric
acid output and symptomatic relief in all patients, but did
notappeartohaveaneﬀectonthehypertrophicGOHforthe
5-year period of the study [20]. This ectopic gastric mucosa
found in the duodenal bulb was present throughout the
durationofthestudy,conﬁrmedbyserialbiopsiesperformed
on the patients every six months.
MEN-I status of the patients was also evaluated. ZES
occurs in about one third of patients with MEN I [21].
In general, MEN I patients experience a less acute form of
the disease and is associated with a genetic predisposition
involving chromosome 11. It is characterized by tumors of
theparathyroid,pancreas,duodenum,andanteriorpituitary.
Tumors in patients with MEN I are smaller, there is lower
rate of metastasis, and the 20-year survival rate is much
higher [22]. In addition, surgical management for patients
with sporadic ZES is more promising; cure is rare following
gastrinoma resection in patients with ZES and MEN I [23].
All of the patients were tested for MEN I status prior to study
enrollment. This biochemical testing included ionized serum
calcium and peptide hormone levels, including parathyroid
hormone, gastrin, insulin, and glucagon [21]. The MEN I4 Diagnostic and Therapeutic Endoscopy
(a) (b)
Figure 1: Heterotopic Gastric Mucosa in the Duodenum unstained (a) and with Methylene Blue-stained Duodenal tissue. (b) These lesions
were seen as macroscopic lesions on endoscopy.
(a) (b)
Figure 2:MicroscopicimagesofendoscopicbiopsyoftheduodenuminpatientswithandwithouthypertrophicGOH.Therelativelynormal
mucosa in patients and areas not aﬀected by hypertrophic GOH (a) demonstrates some villous architecture alterations and gastric foveolar
metaplasia, consistent with peptic type injury. The uninvolved duodenal sections had relatively tall villi, short crypts, and many mucinous
glands both above and beneath the muscularis mucosa. The areas involved with hypertrophic GOH (b) demonstrated hypertrophic oxyntic
gastric mucosa with mature parietal cells.
Figure 3: Microscopic image of hypertrophic GOH in the
Duodenum. The nuclei did not display either polymorphism or
pleomorphism.
gene has been identiﬁed, and current recommendations are
for all family members at risk to be tested annually [21]. No
diﬀerences were evidenced in regards to the presence and
characteristics of GOH between patients with MEN I and
those without.
Fiveoutofthesevenpatients, withanintactstomachand
duodenum, were positive for GOH. Patients with duodenal
GOH experienced higher average baseline gastrin levels and
BAO than those with no GOH in their duodenum (Table 1).
The average values were not statistically signiﬁcant (P>. 05),
however, largely attributable to small sample sizes and large
variances. The potential trend toward higher baseline gastrin
and BAO merits further study.
It has previously been reported that gastric mucosa in
the duodenum with associated duodenitis was linked to the
presence of H. pylori [24]. None of these patients, however,
were diagnosed with ZES. In the present study, none of the
ZES patients were infected with H. pylori, excluding H. pylori
as a potential cause of the observed GOH. For these reasons,
patients with H. pylori were excluded from the study, thus
preventing the presence of a potential confounding variable.Diagnostic and Therapeutic Endoscopy 5
However, this does not exclude the potential for diagnosing
GOH in the presence of H. pylori.
Lee et al. were the ﬁrst to describe tumorous heterotopic
gastric mucosa occurring in the small intestine in 1970
[25]. The series of fourteen cases demonstrated heterotopic
mucosa in either the jejunum or ileum in seven patients.
The heterotopic mucosa, however, was not identiﬁed in
the duodenum of any patients in this series. The patients
reported abdominal pain as being the major symptom, and
ulcers were found in only three of the cases. The heterotopic
mucosa was described as narrow gastric folds, similar in
architecture to the duodenal GOH we identiﬁed in our
patients with ZES.
Recent studies have shown gastrin acts as a growth factor
in the oxyntic mucosa of mice [26]. This supports the
concept that hypergastrinemia could induce ECL cell hyper-
trophy and hyperplasia and in our case contributes to the
growth of hypertrophic GOH, making relatively large lesions
visibleonendoscopyandalsothehistopathologicﬁndingson
histology. Peghini et al. looked at hypergastrinemic diseases
and their proliferative eﬀects on ECL cells. In this study, with
over one hundred patients with ZES, hypergastrinemia was
correlated with ECL cell hyperplasia [27] .T h e r eh a v eb e e n
no studies linking hypergastrinemia to gastric heterotopia
in the duodenum. The fact that our patients suﬀer from
ZES and related gastrinomas, and the trend in our data,
however, suggests that an excess production of gastrin may
be one component in the production of hypertrophic GOH.
We hypothesize that the gastrin which induced hypertrophy
may result in visibility of these lesions on endoscopy more
reliably—increasing the incidence of GOH (>70% in our
study) when compared to the general population with an
incidence of <2%. Another possibility to consider is that
these hypertrophic gastric ectopias may result in pathologic
acid production in the duodenal bulb, resulting in increased
incidence of postbulbar ulcers in patients with ZES—often
the presenting sign. Patients enrolled in this study were on
chronic acid reducing therapy from the time of diagnosis
preventing acid injury of their duodenum, and thus this
could not be evaluated in our subjects. Future studies uti-
lizing endoscopic biopsy to evaluate for hypertrophic GOH
on initial presentation with signs (i.e., postbulbar ulcers),
symptoms, and family history consistent with gastrinoma
would further elucidate the role of hypertrophic GOH.
5. Conclusion
The novel ﬁnding of duodenal gastric heterotopic mucosa
was established in ﬁve of seven patients with ZES and
an intact stomach and intestine and was likely to result
from increased gastrin levels. GOH is thought to be benign
in the general population occurring in about 2 percent
of people. The incidence of hyptertrophic GOH, however,
was 71 percent in our patients with ZES. The presence of
heterotopic and hypertrophic gastric mucosa may result in
gastric acid secretion in the duodenal bulb and contribute
to postbulbar duodenal ulcer development, abdominal pain,
and diarrhea. Furthermore, based on the biopsies taken
at regular intervals during the study, this mucosa neither
improved nor worsened over time with proton pump
inhibitors.
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